Literature DB >> 20193950

Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound.

Toru Miyoshi1, Go Onoue, Atsushi Hirohata, Satoshi Hirohata, Shinichi Usui, Kazuyoshi Hina, Hiroshi Kawamura, Masayuki Doi, Kengo Fukushima Kusano, Shozo Kusachi, Yoshifumi Ninomiya.   

Abstract

OBJECTIVES: Adipocyte fatty acid-binding protein (A-FABP) has been shown to have an effect on insulin resistance, lipid metabolism, and atherosclerosis in animals. We therefore investigated the association between the serum A-FABP level and coronary atherosclerosis.
METHODS: One hundred twenty-five consecutive patients with coronary artery disease (CAD) were enrolled after coronary angiography. Plaque volume in non-culprit coronary arteries was determined using intravascular ultrasound and expressed as percent plaque volume (%PV). Voluntary blood donors (n=120), matched for age and gender, served as controls. Serum levels of A-FABP, adiponectin, and inflammatory markers were measured by enzyme-linked immunosorbent assay.
RESULTS: The serum A-FABP level in CAD patients was significantly higher than in control subjects (median [25th-75th percentiles], 27.2 [20.5-37.1] ng/mL vs. 18.9 [14.6-24.5] ng/mL) (p<0.01). Serum A-FABP showed 0.74 of the area under the curve in the receiver operating characteristic curve for the detection of CAD, with 76% specificity and 65% sensitivity with a cut-off value of 20.1 ng/mL. Further, in CAD patients, serum A-FABP had a significant correlation with %PV in all subjects (r=0.33, p<0.01). Serum A-FABP was positively correlated with the body mass index, serum interleukin-6 and high-sensitive CRP, and negatively correlated with HDL-cholesterol and serum adiponectin in CAD patients. Stepwise regression analysis revealed that serum A-FABP was independently associated with %PV.
CONCLUSION: Increased serum A-FABP was significantly associated with a greater coronary plaque burden. Our findings revealed that the measurement of serum A-FABP could be utilized for the evaluation of the extent of coronary atherosclerosis. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20193950     DOI: 10.1016/j.atherosclerosis.2010.01.032

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  38 in total

1.  Fatty acid-binding proteins as biomarkers of disease severity and outcome in community-acquired pneumonia.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Ann Transl Med       Date:  2016-10

Review 2.  Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?

Authors:  S Kralisch; M Fasshauer
Journal:  Diabetologia       Date:  2012-09-29       Impact factor: 10.122

Review 3.  Small lipid-binding proteins in regulating endothelial and vascular functions: focusing on adipocyte fatty acid binding protein and lipocalin-2.

Authors:  Yu Wang
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

4.  Secretion of fatty acid binding protein aP2 from adipocytes through a nonclassical pathway in response to adipocyte lipase activity.

Authors:  Meric Erikci Ertunc; Jørgen Sikkeland; Federico Fenaroli; Gareth Griffiths; Mathew P Daniels; Haiming Cao; Fahri Saatcioglu; Gökhan S Hotamisligil
Journal:  J Lipid Res       Date:  2014-12-22       Impact factor: 5.922

5.  Fatty acid-binding protein 4 and incident heart failure: the Cardiovascular Health Study.

Authors:  Luc Djoussé; Traci M Bartz; Joachim H Ix; Jinesh Kochar; Jorge R Kizer; John S Gottdiener; Russell P Tracy; Dariush Mozaffarian; David S Siscovick; Kenneth J Mukamal; Susan J Zieman
Journal:  Eur J Heart Fail       Date:  2012-12-06       Impact factor: 15.534

6.  Serum adipocyte fatty acid-binding protein is independently associated with complex coronary lesions in patients with stable coronary artery disease.

Authors:  Masahito Kajiya; Toru Miyoshi; Masayuki Doi; Shinichi Usui; Mutsumi Iwamoto; Ko Takeda; Kazumasa Nosaka; Rie Nakayama; Satoshi Hirohata; Shozo Kusachi; Kazufumi Nakamura; Hiroshi Ito
Journal:  Heart Vessels       Date:  2012-12-09       Impact factor: 2.037

Review 7.  Adipokines as a novel link between obesity and atherosclerosis.

Authors:  Hye Jin Yoo; Kyung Mook Choi
Journal:  World J Diabetes       Date:  2014-06-15

8.  Circulating FABP4 and FABP5 levels are differently linked to OSA severity and treatment.

Authors:  Raquel Català; Anna Cabré; Salvador Hernández-Flix; Raimón Ferré; Sandra Sangenís; Núria Plana; Anna Texidó; Lluís Masana
Journal:  Sleep       Date:  2013-12-01       Impact factor: 5.849

Review 9.  Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment.

Authors:  Meric Erikci Ertunc; Gökhan S Hotamisligil
Journal:  J Lipid Res       Date:  2016-06-21       Impact factor: 5.922

10.  Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trial.

Authors:  Toru Miyoshi; Atsushi Hirohata; Shinichi Usui; Keizo Yamamoto; Takashi Murakami; Issei Komatsubara; Shozo Kusachi; Tohru Ohe; Kazufumi Nakamura; Hiroshi Ito
Journal:  Heart Vessels       Date:  2013-04-07       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.